Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy

被引：44
作者：
Ljunggren, Hans-Gustaf [1 ]
Jonsson, Roland [1 ]
Hoeglund, Petter [1 ]
机构：
[1] Scandinavian Journal Immunol, Bergen, Norway
来源：
SCANDINAVIAN JOURNAL OF IMMUNOLOGY | 2018年 / 88卷 / 06期
关键词：
PD-1;
D O I：
10.1111/sji.12731
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 7 条
[1]   Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer [J].
Hamanishi, Junzo ;
Mandai, Masaki ;
Ikeda, Takafumi ;
Minami, Manabu ;
Kawaguchi, Atsushi ;
Murayama, Toshinori ;
Kanai, Masashi ;
Mori, Yukiko ;
Matsumoto, Shigemi ;
Chikuma, Shunsuke ;
Matsumura, Noriomi ;
Abiko, Kaoru ;
Baba, Tsukasa ;
Yamaguchi, Ken ;
Ueda, Akihiko ;
Hosoe, Yuko ;
Morita, Satoshi ;
Yokode, Masayuki ;
Shimizu, Akira ;
Honjo, Tasuku ;
Konishi, Ikuo .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :4015-+
[2]   INDUCED EXPRESSION OF PD-1, A NOVEL MEMBER OF THE IMMUNOGLOBULIN GENE SUPERFAMILY, UPON PROGRAMMED CELL-DEATH [J].
ISHIDA, Y ;
AGATA, Y ;
SHIBAHARA, K ;
HONJO, T .
EMBO JOURNAL, 1992, 11 (11) :3887-3895
[3]   PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells [J].
Iwai, Y ;
Terawaki, S ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 2005, 17 (02) :133-144
[4]   CD28 AND CTLA-4 HAVE OPPOSING EFFECTS ON THE RESPONSE OF T-CELLS TO STIMULATION [J].
KRUMMEL, MF ;
ALLISON, JP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (02) :459-465
[5]   Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival [J].
Ku, Geoffrey Y. ;
Yuan, Jianda ;
Page, David B. ;
Schroeder, Sebastian E. A. ;
Panageas, Katherine S. ;
Carvajal, Richard D. ;
Chapman, Paul B. ;
Schwartz, Gary K. ;
Allison, James P. ;
Wolchok, Jedd D. .
CANCER, 2010, 116 (07) :1767-1775
[6]   Enhancement of antitumor immunity by CTLA-4 blockade [J].
Leach, DR ;
Krummel, MF ;
Allison, JP .
SCIENCE, 1996, 271 (5256) :1734-1736
[7]   T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors [J].
Sioud, Mouldy .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2018, 87 (03)
1